Matritech (NASDAQ - NMPS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Guy Costa who wrote (391)	4/6/1997 1:43:00 PM
From: William J. Leiby	of 849

Guy: On the week of March 23rd, Montgomery's analyst re-adjusted his revenue forecast for the NMP-22 kit increasing the projected losses, and NOW saying that profitability will not arrive until 1999. He has more than halved the revenue forecast from $4.6 mil to only $2 mil for 1997. (Any wonder why Mr. Corbett unloaded his shares)? This begs the question....what about those HMO (Kaiser) trials that are supposedly going on and supposedly due to end this spring? Indeed, what about Japan's evaluation of the kit that is also supposedly currently being conducted? Its interesting to note that for the last coupla' weeks, if one were to look at Level II, one would notice that Robertson and Montgomery are no longer at the bid. This stock is going to take a lot longer that I anticipated. Also, I want to add that Corbett last year projected $100 mil for the kit. Uh, huh... I want to second the fact that this company has a very dim view of its (individual) shareholders. Bill

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next